These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35054212)

  • 1. Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.
    Kumric M; Zivkovic PM; Ticinovic Kurir T; Vrdoljak J; Vilovic M; Martinovic D; Bratanic A; Lizatovic IK; Bozic J
    Diagnostics (Basel); 2021 Dec; 12(1):. PubMed ID: 35054212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.
    Fu Y; Wang L; Xie C; Zou K; Tu L; Yan W; Hou X
    Sci Rep; 2017 Jun; 7(1):2669. PubMed ID: 28572616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell-activating factor (BAFF) in children with inflammatory bowel disease.
    Fodor I; Serban O; Serban DE; Farcau D; Man SC; Dumitrascu DL
    Pediatr Res; 2021 May; 89(7):1798-1803. PubMed ID: 32937648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.
    Zhang P; Liu X; Guo A; Xiong J; Fu Y; Zou K
    Dig Dis Sci; 2016 Sep; 61(9):2608-18. PubMed ID: 27056038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy.
    Piantoni S; Regola F; Masneri S; Merletti M; Lowin T; Airò P; Tincani A; Franceschini F; Andreoli L; Pongratz G
    Front Pharmacol; 2021; 12():666971. PubMed ID: 34093196
    [No Abstract]   [Full Text] [Related]  

  • 6. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
    Shin W; Lee HT; Lim H; Lee SH; Son JY; Lee JU; Yoo KY; Ryu SE; Rhie J; Lee JY; Heo YS
    Nat Commun; 2018 Mar; 9(1):1200. PubMed ID: 29572471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.
    Uzzan M; Colombel JF; Cerutti A; Treton X; Mehandru S
    Dig Dis Sci; 2016 Dec; 61(12):3407-3424. PubMed ID: 27655102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia.
    Tandler C; Schmidt M; Heitmann JS; Hierold J; Schmidt J; Schneider P; Dörfel D; Walz J; Salih HR
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32977449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia.
    Rihacek M; Bienertova-Vasku J; Valik D; Sterba J; Pilatova K; Zdrazilova-Dubska L
    Biomed Res Int; 2015; 2015():792187. PubMed ID: 26339644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE).
    Möckel T; Basta F; Weinmann-Menke J; Schwarting A
    Autoimmun Rev; 2021 Feb; 20(2):102736. PubMed ID: 33333233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.
    Gacesa R; Vich Vila A; Collij V; Mujagic Z; Kurilshikov A; Voskuil MD; Festen EAM; Wijmenga C; Jonkers DMAE; Dijkstra G; Fu J; Zhernakova A; Imhann F; Weersma RK
    Gut Microbes; 2021; 13(1):1943288. PubMed ID: 34313538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease].
    Li L; Liu HY; Wang LJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2024 Mar; 26(3):315-320. PubMed ID: 38557386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
    Konikoff MR; Denson LA
    Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel disease detection and monitoring by measuring biomarkers in non-invasively collected colorectal mucus.
    Loktionov A; Chhaya V; Bandaletova T; Poullis A
    J Gastroenterol Hepatol; 2017 May; 32(5):992-1002. PubMed ID: 27787913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
    World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.